Open AccessModern Genetic Engineering Technology Achievements in Rheumatology
Author(s) -
T I Okonenko,
A K Khrutskiy,
A B Yershevskaya,
А. В. Иванова,
G A Antropova,
Yegor Y. Rumyantsev
Publication year - 2021
Publication title -
iop conference series. earth and environmental science
Language(s) - English
Resource type - Journals
eISSN - 1755-1307
pISSN - 1755-1315
DOI - 10.1088/1755-1315/852/1/012075
Subject(s) - medicine , rheumatoid arthritis , rheumatology , biological drugs , oncology , rheumatic disease , disease , russian federation , combination therapy , intensive care medicine , business , economic policy
The paper provides an overview of modern genetically engineered biological agents (GEBAs) used in the treatment of rheumatoid arthritis (RA) in the Russian Federation. The spectrum of medicinal agents of this group used in the Novgorod region has been analyzed. The analysis of treatment regimens of 68 patients demonstrates high efficiency of combination therapy of GEBAs and disease modifying anti-rheumatic drugs due to a decrease in the activity of the process of more than 78 % of the patients and to achieving remission of 2.9 % of them. It is indicated that GEBAs therapy requires careful screening procedures of patients, exclusion of infectious processes, cancer and severe pathology of internal organs. The reasons for the difficulties in achieving remission against the background of GEBAs therapy of the observed patients, as well as complications arising during the treatment, are given.